{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.68","value":"66.52"},{"groupId":"OG001","spread":"22.00","value":"63.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"title":"Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.33","value":"-3.54"},{"groupId":"OG001","spread":"21.77","value":"-2.48"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"218"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.92","value":"-2.91"},{"groupId":"OG001","spread":"23.04","value":"-1.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"86"},{"groupId":"OG001","value":"182"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.61","value":"-2.71"},{"groupId":"OG001","spread":"22.21","value":"-2.25"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"80"},{"groupId":"OG001","value":"167"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.26","value":"0.65"},{"groupId":"OG001","spread":"25.35","value":"-1.43"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"134"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 5"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.99","value":"-0.14"},{"groupId":"OG001","spread":"22.94","value":"0.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"119"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.26","value":"3.01"},{"groupId":"OG001","spread":"22.74","value":"1.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"94"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.87","value":"5.28"},{"groupId":"OG001","spread":"23.17","value":"0.72"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"81"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 10"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.45","value":"6.19"},{"groupId":"OG001","spread":"18.56","value":"-2.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"},{"groupId":"OG001","value":"69"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.42","value":"7.50"},{"groupId":"OG001","spread":"19.67","value":"1.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"30"},{"groupId":"OG001","value":"60"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 14"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.77","value":"6.55"},{"groupId":"OG001","spread":"18.52","value":"1.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"53"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.11","value":"4.71"},{"groupId":"OG001","spread":"17.56","value":"0.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"50"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 18"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.73","value":"9.52"},{"groupId":"OG001","spread":"18.52","value":"-0.95"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"44"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 20"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.20","value":"5.56"},{"groupId":"OG001","spread":"19.92","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"36"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 22"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.20","value":"7.29"},{"groupId":"OG001","spread":"18.99","value":"-2.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 24"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"24.95","value":"1.56"},{"groupId":"OG001","spread":"21.51","value":"-2.15"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 26"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.72","value":"1.79"},{"groupId":"OG001","spread":"21.17","value":"1.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"23"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 28"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"16.45","value":"5.77"},{"groupId":"OG001","spread":"21.81","value":"3.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"21"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 30"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.46","value":"0.00"},{"groupId":"OG001","spread":"17.91","value":"0.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"22"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 32"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"20.07","value":"0.00"},{"groupId":"OG001","spread":"19.70","value":"2.50"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 34"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.73","value":"-1.52"},{"groupId":"OG001","spread":"20.52","value":"1.67"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"20"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 36"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.11","value":"2.27"},{"groupId":"OG001","spread":"20.66","value":"3.70"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 38"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.50","value":"5.30"},{"groupId":"OG001","spread":"19.85","value":"1.39"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 40"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.25","value":"0.00"},{"groupId":"OG001","spread":"20.37","value":"2.31"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"18"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 42"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"18.23","value":"2.08"},{"groupId":"OG001","spread":"19.95","value":"3.65"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"16"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 44"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"25.88","value":"2.08"},{"groupId":"OG001","spread":"21.60","value":"2.45"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"17"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 46"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"15.54","value":"7.14"},{"groupId":"OG001","spread":"20.35","value":"4.17"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 48"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"17.16","value":"-2.38"},{"groupId":"OG001","spread":"21.82","value":"3.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 50"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.91","value":"8.33"},{"groupId":"OG001","spread":"16.76","value":"-3.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 52"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"12.73","value":"-2.78"},{"groupId":"OG001","spread":"22.27","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"8"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 54"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.89","value":"4.17"},{"groupId":"OG001","spread":"4.81","value":"2.78"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 56"},{"categories":[{"measurements":[{"comment":"SD was not estimable since only 1 participant was evaluated.","groupId":"OG000","spread":"NA","value":"0.00"},{"groupId":"OG001","spread":"0.00","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 58"},{"categories":[{"measurements":[{"comment":"SD was not estimable since only 1 participant was evaluated.","groupId":"OG000","spread":"NA","value":"8.33"},{"comment":"SD was not estimable since only 1 participant was evaluated.","groupId":"OG001","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 60"},{"categories":[{"measurements":[{"comment":"SD was not estimable since only 1 participant was evaluated.","groupId":"OG000","spread":"NA","value":"-8.33"},{"comment":"SD was not estimable since only 1 participant was evaluated.","groupId":"OG001","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 62"},{"categories":[{"measurements":[{"comment":"SD was not estimable since only 1 participant was evaluated.","groupId":"OG001","spread":"NA","value":"0.00"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}],"units":"Participants"}],"title":"Change at Day 1 Cycle 64"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.28","value":"-14.53"},{"groupId":"OG001","spread":"25.42","value":"-13.37"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"149"}],"units":"Participants"}],"title":"Change at Treatment Discontinuation Visit"}],"denoms":[{"counts":[{"groupId":"OG000","value":"117"},{"groupId":"OG001","value":"242"}],"units":"Participants"}],"description":"EORTC IL57 questionnaire has 10 items and covers 3 scales: PF, RF \\& GHS/QoL \\& 1 item from EORTC IL. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks \\& short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work \\& pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health \\& QoL in previous week. Questions are answered on a 4-point Likert scale (where 1=\"Not at all\" to 4=\"Very much\") for physical and role functioning \\& a 7-point scale (where 1=\"Very poor\" to 7=\"Excellent\") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 = best possible score. Higher score indicates better outcome.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received atezolizumab, 1200 mg, as an IV infusion, Q3W, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG000","title":"Part 2: Atezolizumab IV 1200 mg"},{"description":"Participants received atezolizumab, 1875 mg, co-formulated with rHuPH20, as SC injection, on Day 1 of each cycle (1 cycle=21 days) until PD, loss of clinical benefit, or unacceptable toxicity.","id":"OG001","title":"Part 2: Atezolizumab SC 1875 mg"}],"paramType":"MEAN","populationDescription":"FAS included all randomized participants, with participants grouped according to their assigned treatment. Overall number analyzed is the number of participants with data available for analysis. Number analyzed is the number of participants with data available for analysis at the specified time point.","reportingStatus":"POSTED","timeFrame":"Baseline, Day 1 of Cycles 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64 (Cycle length = 21 days), and Treatment Discontinuation Visit (up to approximately 44 months)","title":"Part 2: Change From Baseline in EORTC IL57 Global Health Status Score","type":"SECONDARY","unitOfMeasure":"score on a scale"}